Berberine inhibits HIF-1α expression via enhanced proteolysis

Shankung Lin, Shiow Chwen Tsai, Chun Chung Lee, Bao Wei Wang, Jer Young Liou, Kou Gi Shyu

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

We have studied the antiangiogenic property of berberine. We showed that berberine could directly inhibit in vitro human umbilical vein endothelial cell (HUVEC) tube formation and migration. In addition, to determine whether berberine could influence the cross-talk between the gastric adenocarcinoma cell line SC-M1 and vascular endothelial cells, we performed modified confrontation culture experiments and showed that berberine (7.5 μM, 16 h) could inhibit the capacity of hypoxic SC-M1 cells to stimulate HUVEC migration. These results demonstrated berberine's antiangiogenic property and its clinical potential as an inhibitor of tumor angiogenesis. Parallel Western blot analyses revealed that berberine prevented hypoxic SC-M1 cultures from expressing vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF)-1α, two key factors in mediating tumor angiogenesis. However, overexpression of HIF-1α in SC-M1 cells dramatically reversed the inhibitory effect of berberine on SC-M1-induced in vitro HUVEC migration. These data indicated that HIF-1α repression is a critical step in the inhibitory effect of berberine on tumor-induced angiogenesis. Northern blot analyses plus pulse-chase assays revealed that berberine did not down-regulate HIF-1α mRNA but destabilized HIF-1α protein. We found that berberine-induced HIF-1α degradation was blocked by a 26S proteasome inhibitor. Moreover, immunoprecipitation and Western blot analyses showed that berberine increased the lysine-acetylated HIF-1α in hypoxic SC-M1 cultures. These data indicated that a proteasomal proteolytic pathway and lysine acetylation were involved in berberine-triggered HIF-1α degradation. In conclusion, our data provided molecular evidence to support berberine as a potent antiangiogenic agent in cancer therapy.

Original languageEnglish
Pages (from-to)612-619
Number of pages8
JournalMolecular Pharmacology
Volume66
Issue number3
Publication statusPublished - Sep 2004

Fingerprint

Berberine
Hypoxia-Inducible Factor 1
Proteolysis
Human Umbilical Vein Endothelial Cells
Angiogenesis Inhibitors
Lysine
Cell Movement
Neoplasms
Western Blotting
Proteasome Inhibitors
Acetylation
Immunoprecipitation
Northern Blotting
Vascular Endothelial Growth Factor A

ASJC Scopus subject areas

  • Pharmacology

Cite this

Lin, S., Tsai, S. C., Lee, C. C., Wang, B. W., Liou, J. Y., & Shyu, K. G. (2004). Berberine inhibits HIF-1α expression via enhanced proteolysis. Molecular Pharmacology, 66(3), 612-619.

Berberine inhibits HIF-1α expression via enhanced proteolysis. / Lin, Shankung; Tsai, Shiow Chwen; Lee, Chun Chung; Wang, Bao Wei; Liou, Jer Young; Shyu, Kou Gi.

In: Molecular Pharmacology, Vol. 66, No. 3, 09.2004, p. 612-619.

Research output: Contribution to journalArticle

Lin, S, Tsai, SC, Lee, CC, Wang, BW, Liou, JY & Shyu, KG 2004, 'Berberine inhibits HIF-1α expression via enhanced proteolysis', Molecular Pharmacology, vol. 66, no. 3, pp. 612-619.
Lin S, Tsai SC, Lee CC, Wang BW, Liou JY, Shyu KG. Berberine inhibits HIF-1α expression via enhanced proteolysis. Molecular Pharmacology. 2004 Sep;66(3):612-619.
Lin, Shankung ; Tsai, Shiow Chwen ; Lee, Chun Chung ; Wang, Bao Wei ; Liou, Jer Young ; Shyu, Kou Gi. / Berberine inhibits HIF-1α expression via enhanced proteolysis. In: Molecular Pharmacology. 2004 ; Vol. 66, No. 3. pp. 612-619.
@article{7bdc4a96f98947d18d8df2103c34bb78,
title = "Berberine inhibits HIF-1α expression via enhanced proteolysis",
abstract = "We have studied the antiangiogenic property of berberine. We showed that berberine could directly inhibit in vitro human umbilical vein endothelial cell (HUVEC) tube formation and migration. In addition, to determine whether berberine could influence the cross-talk between the gastric adenocarcinoma cell line SC-M1 and vascular endothelial cells, we performed modified confrontation culture experiments and showed that berberine (7.5 μM, 16 h) could inhibit the capacity of hypoxic SC-M1 cells to stimulate HUVEC migration. These results demonstrated berberine's antiangiogenic property and its clinical potential as an inhibitor of tumor angiogenesis. Parallel Western blot analyses revealed that berberine prevented hypoxic SC-M1 cultures from expressing vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF)-1α, two key factors in mediating tumor angiogenesis. However, overexpression of HIF-1α in SC-M1 cells dramatically reversed the inhibitory effect of berberine on SC-M1-induced in vitro HUVEC migration. These data indicated that HIF-1α repression is a critical step in the inhibitory effect of berberine on tumor-induced angiogenesis. Northern blot analyses plus pulse-chase assays revealed that berberine did not down-regulate HIF-1α mRNA but destabilized HIF-1α protein. We found that berberine-induced HIF-1α degradation was blocked by a 26S proteasome inhibitor. Moreover, immunoprecipitation and Western blot analyses showed that berberine increased the lysine-acetylated HIF-1α in hypoxic SC-M1 cultures. These data indicated that a proteasomal proteolytic pathway and lysine acetylation were involved in berberine-triggered HIF-1α degradation. In conclusion, our data provided molecular evidence to support berberine as a potent antiangiogenic agent in cancer therapy.",
author = "Shankung Lin and Tsai, {Shiow Chwen} and Lee, {Chun Chung} and Wang, {Bao Wei} and Liou, {Jer Young} and Shyu, {Kou Gi}",
year = "2004",
month = "9",
language = "English",
volume = "66",
pages = "612--619",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Berberine inhibits HIF-1α expression via enhanced proteolysis

AU - Lin, Shankung

AU - Tsai, Shiow Chwen

AU - Lee, Chun Chung

AU - Wang, Bao Wei

AU - Liou, Jer Young

AU - Shyu, Kou Gi

PY - 2004/9

Y1 - 2004/9

N2 - We have studied the antiangiogenic property of berberine. We showed that berberine could directly inhibit in vitro human umbilical vein endothelial cell (HUVEC) tube formation and migration. In addition, to determine whether berberine could influence the cross-talk between the gastric adenocarcinoma cell line SC-M1 and vascular endothelial cells, we performed modified confrontation culture experiments and showed that berberine (7.5 μM, 16 h) could inhibit the capacity of hypoxic SC-M1 cells to stimulate HUVEC migration. These results demonstrated berberine's antiangiogenic property and its clinical potential as an inhibitor of tumor angiogenesis. Parallel Western blot analyses revealed that berberine prevented hypoxic SC-M1 cultures from expressing vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF)-1α, two key factors in mediating tumor angiogenesis. However, overexpression of HIF-1α in SC-M1 cells dramatically reversed the inhibitory effect of berberine on SC-M1-induced in vitro HUVEC migration. These data indicated that HIF-1α repression is a critical step in the inhibitory effect of berberine on tumor-induced angiogenesis. Northern blot analyses plus pulse-chase assays revealed that berberine did not down-regulate HIF-1α mRNA but destabilized HIF-1α protein. We found that berberine-induced HIF-1α degradation was blocked by a 26S proteasome inhibitor. Moreover, immunoprecipitation and Western blot analyses showed that berberine increased the lysine-acetylated HIF-1α in hypoxic SC-M1 cultures. These data indicated that a proteasomal proteolytic pathway and lysine acetylation were involved in berberine-triggered HIF-1α degradation. In conclusion, our data provided molecular evidence to support berberine as a potent antiangiogenic agent in cancer therapy.

AB - We have studied the antiangiogenic property of berberine. We showed that berberine could directly inhibit in vitro human umbilical vein endothelial cell (HUVEC) tube formation and migration. In addition, to determine whether berberine could influence the cross-talk between the gastric adenocarcinoma cell line SC-M1 and vascular endothelial cells, we performed modified confrontation culture experiments and showed that berberine (7.5 μM, 16 h) could inhibit the capacity of hypoxic SC-M1 cells to stimulate HUVEC migration. These results demonstrated berberine's antiangiogenic property and its clinical potential as an inhibitor of tumor angiogenesis. Parallel Western blot analyses revealed that berberine prevented hypoxic SC-M1 cultures from expressing vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF)-1α, two key factors in mediating tumor angiogenesis. However, overexpression of HIF-1α in SC-M1 cells dramatically reversed the inhibitory effect of berberine on SC-M1-induced in vitro HUVEC migration. These data indicated that HIF-1α repression is a critical step in the inhibitory effect of berberine on tumor-induced angiogenesis. Northern blot analyses plus pulse-chase assays revealed that berberine did not down-regulate HIF-1α mRNA but destabilized HIF-1α protein. We found that berberine-induced HIF-1α degradation was blocked by a 26S proteasome inhibitor. Moreover, immunoprecipitation and Western blot analyses showed that berberine increased the lysine-acetylated HIF-1α in hypoxic SC-M1 cultures. These data indicated that a proteasomal proteolytic pathway and lysine acetylation were involved in berberine-triggered HIF-1α degradation. In conclusion, our data provided molecular evidence to support berberine as a potent antiangiogenic agent in cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=4944248618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4944248618&partnerID=8YFLogxK

M3 - Article

C2 - 15322253

AN - SCOPUS:4944248618

VL - 66

SP - 612

EP - 619

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 3

ER -